Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for Chronic Obstructive Pulmonary Disease (COPD), specifically in patients who also have chronic bronchitis. The treatment being tested is called CHF6001 DPI, which is an inhalation powder containing the active substance tanimilast. The study will also involve a medication called Roflumilast (Daliresp®), which is available in tablet form. Some participants will receive a placebo, which looks like the real medication but does not contain any active ingredients.

The purpose of the study is to evaluate how effective and safe two different doses of CHF6001 DPI are when added to the usual maintenance therapy for COPD. This maintenance therapy typically includes a combination of inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA). The study will last for 52 weeks, during which participants will be randomly assigned to different groups. Some will receive CHF6001 DPI along with their regular treatment, while others will receive Roflumilast or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will be monitored to see how the treatments affect their COPD symptoms, particularly the frequency and severity of flare-ups, also known as exacerbations. The study will also assess changes in lung function and quality of life. By the end of the study, researchers hope to determine whether adding CHF6001 DPI to the standard COPD treatment can help reduce the number of moderate and severe exacerbations in patients with COPD and chronic bronchitis.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants are required to provide written informed consent. This confirms understanding of the study procedures and agreement to participate.

    Participants must be at least 40 years old and have a confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with chronic bronchitis.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to confirm eligibility. This includes a review of medical history, smoking history, and current symptoms.

    Participants must have a history of at least one moderate or severe COPD exacerbation in the previous year and be on maintenance triple therapy for at least 12 months prior to the screening.

  3. Step 3

    Randomization and treatment allocation

    Participants are randomly assigned to one of the treatment groups. This process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered.

    The study involves the use of CHF6001 DPI, Roflumilast (Daliresp®) 500µg, and Roflumilast (Daliresp®) 250µg, as well as corresponding placebos.

  4. Step 4

    Treatment administration

    Participants receive their assigned treatment for a duration of 52 weeks. CHF6001 DPI is administered via inhalation, while Roflumilast is taken orally in tablet form.

    The frequency and dosage depend on the specific treatment group to which the participant is assigned.

  5. Step 5

    Ongoing monitoring and assessments

    Throughout the study, participants undergo regular monitoring to assess the efficacy and safety of the treatment. This includes spirometry tests and questionnaires to evaluate symptoms and quality of life.

    Participants are required to use electronic devices to complete COPD questionnaires and perform required outcome measurements.

  6. Step 6

    Completion of the study

    At the end of the 52-week period, participants complete a final assessment to evaluate the overall impact of the treatment.

    The primary goal is to measure the annual rate of moderate and severe exacerbations, while secondary goals include changes in symptom scores and lung function.

Who can join the trial?

10 criteria

  • Males and females aged 40 years or older who have given written permission to participate in the study.
  • Participants must be willing and able to learn how to use electronic devices for answering questions about their condition and performing necessary tests, like breathing tests.
  • Women can join the study if they cannot have children or, if they can have children, they must have a negative pregnancy test and agree to use birth control.
  • Participants must have a confirmed diagnosis of **Chronic Obstructive Pulmonary Disease (COPD)** with **chronic bronchitis**.
  • Current smokers or those who quit smoking at least 6 months before the study, with a history of smoking at least 10 pack years. A "pack year" is a way to measure how much someone has smoked over time.
  • Participants must have a specific lung function test result, showing less than 50% of the expected normal value after using a medicine that helps open the airways.
  • Participants must have had at least one moderate or severe worsening of their COPD in the past year, as confirmed by medical records.
  • Participants must have symptoms at the start of the study, shown by a **CAT score** of 10 or more. The CAT score is a questionnaire that measures the impact of COPD on a person's life.
  • Participants must have been prescribed a combination of three types of COPD medicines (ICS, LABA, LAMA) for at least 12 months before the study and have been regularly using them for at least 3 months before the study starts. ICS must be in an approved dose for COPD.
  • Participants must be willing and able to learn how to use a specific type of inhaler called **DPI inhalers (NEXThaler®)**.

Who cannot join the trial?

9 criteria

  • Patients who have a different lung condition other than Chronic Obstructive Pulmonary Disease (COPD).
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to follow the study procedures or take the study medication as required.
  • Patients who have a medical condition that might interfere with the study results or pose a risk to their health.
  • Patients who are pregnant or breastfeeding.
  • Patients who are participating in another clinical trial at the same time.
  • Patients who have a history of substance abuse that might affect their ability to participate in the study.
  • Patients who have had a recent major surgery or are planning to have surgery during the study period.
  • Patients who have a known allergy or sensitivity to the study medication or its ingredients.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Roflumilast

    This medication is used to reduce inflammation in the lungs and is often prescribed for people with severe Chronic Obstructive Pulmonary Disease (COPD) to help prevent flare-ups. It works by decreasing swelling and irritation in the airways, making it easier to breathe.

  • Daliresp

    This is a brand name for roflumilast, which is used to treat COPD. It helps to prevent the worsening of symptoms by reducing inflammation in the lungs.

  • CHF6001

    This is an investigational medication being studied as an add-on treatment for COPD. It is being tested to see if it can further reduce the frequency of moderate and severe exacerbations when used alongside standard maintenance therapy. The goal is to improve breathing and reduce the number of flare-ups in patients with COPD and chronic bronchitis.

  • ICS, LABA, LAMA

    These are types of medications commonly used in combination as maintenance therapy for COPD. ICS stands for inhaled corticosteroids, which help reduce inflammation in the airways. LABA stands for long-acting beta-agonists, which help relax the muscles around the airways to keep them open. LAMA stands for long-acting muscarinic antagonists, which also help to keep the airways open by blocking certain receptors in the lungs. These medications are often used together to help manage COPD symptoms and prevent exacerbations.

What is already known about the treatment

  • Roflumilast

    Roflumilast is administered orally in tablet form and is currently approved for use in treating Chronic Obstructive Pulmonary Disease (COPD). It is well-documented in medical literature as an effective treatment for reducing inflammation in the lungs. The main therapeutic indication for Roflumilast is to decrease the frequency of flare-ups or worsening of symptoms in patients with severe COPD. At the molecular level, it works by inhibiting an enzyme called phosphodiesterase-4 (PDE4), which leads to a reduction in inflammation. Roflumilast is classified as a phosphodiesterase inhibitor.

  • CHF6001

    CHF6001 is administered via a dry powder inhaler and is currently being evaluated in clinical trials for its effectiveness in treating Chronic Obstructive Pulmonary Disease (COPD). It is not yet widely available in medical practice but shows promise in reducing the rate of moderate and severe exacerbations in COPD patients. The main therapeutic indication is to serve as an add-on therapy to existing maintenance treatments for COPD. CHF6001 works by inhibiting the phosphodiesterase-4 (PDE4) enzyme, which helps to reduce inflammation in the airways. It is classified as a phosphodiesterase inhibitor.

Investigated diseases

Chronic Obstructive Pulmonary Disease (COPD) – This is a long-term lung disease that makes it hard to breathe. It is characterized by a persistent blockage of airflow from the lungs, which is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. The main symptoms include breathing difficulty, cough, mucus (sputum) production, and wheezing. People with COPD are at increased risk of developing heart disease, lung cancer, and a variety of other conditions. The disease progresses over time, leading to worsening symptoms and decreased lung function. Exacerbations, or episodes of worsening symptoms, are common and can be triggered by infections or environmental pollutants.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-510174-13-00Protocol codeCLI-06001AA1-05Estimated enrolment3 978 patientsSponsorChiesi Farmaceutici S.p.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.